Evidence map›Paper›PMID 35378863›Full record

ArticleiScience2022

Real-time and automated monitoring of antischistosomal drug activity profiles for screening of compound libraries.

Paolo S Ravaynia, Stefan Biendl, Francesco Grassi, Jennifer Keiser, Andreas Hierlemann, Mario M Modena

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Paolo S RavayniaBioengineering Laboratory, Department of Biosystems Science and Engineering, ETH Zürich, Mattenstrasse 26, 4058 Basel, Switzerland.
Stefan BiendlSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, University of Basel, Socinstrasse 57, 4051 Basel, Switzerland.
Francesco GrassiCentre for Microsystems Technology, Department of Electronics and Information Systems, Ghent University, Technologiepark-Zwijnaarde 126, 9052 Gent, Belgium.
Jennifer KeiserSwiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, University of Basel, Socinstrasse 57, 4051 Basel, Switzerland.
Andreas HierlemannBioengineering Laboratory, Department of Biosystems Science and Engineering, ETH Zürich, Mattenstrasse 26, 4058 Basel, Switzerland.
Mario M ModenaBioengineering Laboratory, Department of Biosystems Science and Engineering, ETH Zürich, Mattenstrasse 26, 4058 Basel, Switzerland.
ETH Zurich · CHSwiss Tropical and Public Health Institute · CHGhent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schistosomiasis is a neglected tropical disease that affects over 200 million people annually. As the antischistosomal drug pipeline is currently empty, repurposing of compound libraries has become a source for accelerating drug development, which demands the implementation of high-throughput and efficient screening strategies. Here, we present a parallelized impedance-based platform for continuous and automated viability evaluation of

Indexed as

BiotechnologyDrugsMicrobiology parasiteMonitoring featureSignal processing

Identifiers

PMID35378863
PMCPMC8976133
OpenAlexW4220791973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.